Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine

Drug Profile

Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine

Alternative Names: Chlorhexidine/silver sulfadiazine/recombinant epidermal growth factor; Recombinant epidermal growth factor/chlorhexidine/silver sulfadiazine; Recombinant epidermal growth factor/silver sulfadiazine/chlorhexidine; rhEGF/silver sulfadiazine/chlorhexidine gluconate; Silver sulfadiazine/chlorhexidine/recombinant epidermal growth factor; Silver sulfadiazine/recombinant epidermal growth factor/chlorhexidine; SLVRGEN

Latest Information Update: 20 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bharat Biotech
  • Class Antibacterials; Antiseptics; Growth factors; Heavy metals; Skin disorder therapies; Sulfonamides
  • Mechanism of Action Epidermal growth factor receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Burns

Most Recent Events

  • 31 Dec 2010 Launched for Burns in India (Topical) prior to December 2010
  • 31 Dec 2010 Registered for Burns in India (Topical) prior to December 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top